



Biotech Daily

Tuesday September 10, 2024

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: AMPLIA UP 10%; PRESCIENT DOWN 6%**
- * **AUDEARA TO LICENCE TECHNOLOGY TO EASTECH FOR CHINA**
- * **IMAGION \$550,000 MERCER CONVERTIBLE NOTES PROSPECTUS**
- * **DIMERIX STARTS DMX-200 FSGS OPEN-LABEL EXTENSION STUDY**
- * **EMVISION: M-D SCOTT KIRKLAND INCREASES, DILUTED 'BELOW 5%'**
- * **ALLAN GREY BELOW 5% IN STARPHARMA**

MARKET REPORT

The Australian stock market was up 0.3 percent on Tuesday September 10, 2024, with the ASX200 up 23.8 points to 8,011.9 points.

Nineteen of the Biotech Daily Top 40 companies were up, 14 were down and seven traded unchanged.

Amplia was Tuesday's best, up one cent or 10.0 percent to 11 cents, with 683,734 shares traded.

Universal Biosensors improved 7.7 percent; Paradigm climbed 6.4 percent; Polynovo was up 5.1 percent; Orthocell rose 4.55 percent; Syntara and Telix were up more than three percent; 4D Medical, Cyclopharm, Medadvisor, Nanosonics and Percheron rose more than two percent; Avita, Clinuvel, Emission, Medical Developments and Resmed were up one percent or more; with CSL, Genetic Signatures, Neuren and Pro Medicus up by less than one percent.

Prescient led the falls, down 0.3 cents or 6.4 percent to 4.4 cents, with 1.6 million shares traded.

Aroa lost five percent; Impedimed fell 4.35 percent; Compumedics and Dimerix were down more than three percent; Actinogen, Atomo, Curvebeam and Nova Eye shed more than two percent; Cochlear, Immutep, Mesoblast and Starpharma were down more than one percent; with Clarity and Proteomics down by less than one percent.

AUDEARA

Audeara says Hong Kong's Eastech will licence its hearing device technology for products in China, for a yet-to-be determined price.

Audeara said Eastech provided technology for various industries and was expanding to offer medical audio device products and would "enable the development and realization" of hearing devices, under Eastech's National Medical Products Administration certification. Audeara said it expected the devices to be marketed under brands "with strong market recognition in China".

Audeara said the agreement was "not subject to term or termination" and the financial impact was subject to the terms of a product specific licencing or services agreement. The company said that in 2019 about 426.5 million people in China had hearing loss with 331.4 million people having mild hearing loss and more than 95 million people with moderate to complete hearing loss.

Audeara was up 0.1 cents or 2.8 percent to 3.7 cents.

IMAGION BIOSYSTEMS

Imagion says it is offering Mercer Street 550,000 convertible notes with a face value of \$1.00 each and a subscription price of 90.909 cents and up to 20,833,333 options.

Imagion said the Miami, Florida-based Mercer Street Global Opportunity Fund LLC would subscribe for up to 550,000 notes, with the 20,833,333 options exercisable at 140 percent of the 20-day volume-weighted average price to the date of issue within 36 months.

The company said the funds would be used for general working capital.

Imagion fell 0.3 cents or 9.7 percent to 2.8 cents.

DIMERIX

Dimerix says it has begun an open-label extension study to follow its randomized, phase III trial of DMX-200 for focal segmental glomerulo-sclerosis (FSGS) kidney disease.

In 2022, Dimerix said it had recruited the first of 286 patients in the phase III trial of DMX200 for kidney disease; with proteinuria, or percentage of protein in the urine, and estimated glomerular filtration rate, as primary endpoints (BD: May 31, 2022).

In March, the company said that an interim analysis of 72 patients showed DMX-200 reduced proteinuria more than placebo (BD: Mar 11, 2024).

Today, Dimerix said that 116 patients had been dosed or randomized in the Action3 phase II trial and the extension study was optional for all patients who had completed the phase III trial, evaluating the longer-term safety and efficacy of DMX-200.

The company said patients would receive DMX-200, regardless of whether they received the drug or a placebo during the phase III trial, and would continue on the background standard-of-care blood pressure medication, angiotensin receptor blocker (ARBs) and be treated for two years with DMX-200.

Dimerix said, at the end of the treatment period, it would evaluate the change in urine protein to creatinine ratio, as well as the change in estimated glomerular filtration rate, both of which were markers of drug efficacy, and compare patients who received placebo in the initial study to those who received DMX-200.

Dimerix chief medical officer Dr David Fuller "the open-label extension study will provide us with additional longer term information regarding treatment with DMX-200, and we are pleased to be able to provide the active drug to all patients who complete the [phase III trial], irrespective of treatment arm".

Dimerix fell 1.5 cents or 3.7 percent to 39 cents with 9.5 million shares traded.

EMVISION MEDICAL DEVICES

Emvision managing director Scott Kirkland says he has increased his shareholding but been diluted below five percent in the company.

The Sydney-based Mr Kirkland said that on December 22, 2021 he was issued 520,755 shares through the exercise of options for no consideration, and on January 12, 2022 bought 7,832 for \$20,050 or \$2.56 a share.

Mr Kirkland said that on September 10, 2024 his 4,276,987 shareholding was diluted as a result of additional shares issue by the company "since the prior notice".

In 2020, Mr Kirkland said that he held 3,748,400 shares (5.34%) (BD: Jul 31, 2020).

According to its latest filing, Emvision said it had 85,516,535 shares on issue, with Biotech Daily calculating Mr Kirkland's holding at 5.0014 percent.

Emvision was up two cents or one percent to \$2.07.

STARPHARMA HOLDINGS

Allan Gray says it has ceased its Starpharma substantial holding, selling 2,850,561 shares for \$274,749 or 9.6 cents a share between August 24 and September 5, 2024.

Last month, Sydney's Allan Gray Australia said that it held 23,690,480 Starpharma shares (5.74%) (BD: Aug 28, 2024).

In its latest filing, Starpharma said it had 417,367,662 shares on issue, with Biotech Daily calculating Allan Gray's 20,839,919 shareholding to be 4.993 percent of the company.

Starpharma fell 0.1 cents or 1.05 percent to 9.4 cents.